Amedeo Smart

Free Medical Literature Service


 

Amedeo

Chronic Heart Failure

  Free Subscription

Articles published in
J Cardiovasc Pharmacol
    July 2021
  1. SHRESTHA DB, Budhathoki P, Sedhai YR, Karki P, et al
    SGLT-2 inhibitors in heart failure: An updated systematic review and meta-analysis of 13 randomized clinical trials including 14618 patients with heart failure.
    J Cardiovasc Pharmacol. 2021 Jul 9. pii: 00005344-900000000-98175.
    >> Share

  2. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
    Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
    J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
    >> Share

    June 2021
  3. ADIE SK, Ketcham SW, Abdul-Aziz AA, Thomas MP, et al
    Characteristics of heart failure patients with or without hypotension when transitioning from nitroprusside to sacubitril-valsartan.
    J Cardiovasc Pharmacol. 2021 Jun 21. pii: 00005344-900000000-98191.
    >> Share

    May 2021
  4. NANDKEOLYAR S, Ryu R, Mohammed A, Cordero-Caban K, et al
    A Review of Inotropes and Inopressors for Effective Utilization in Patients with Acute Decompensated Heart Failure.
    J Cardiovasc Pharmacol. 2021 May 28. pii: 00005344-900000000-98208.
    >> Share

    April 2021
  5. LONG YX, Cui DY, Kuang X, Hu S, et al
    Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98238.
    >> Share

    February 2021
  6. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    >> Share

    December 2020
  7. RERICK L, Elston C, Kester J, Montepara C, et al
    Evaluation of sacubitril/valsartan initiation in outpatient heart failure patients.
    J Cardiovasc Pharmacol. 2020 Dec 1. doi: 10.1097/FJC.0000000000000966.
    >> Share

    November 2020
  8. WOHLFORD GF, Van Tassell BW, Billingsley HE, Kadariya D, et al
    A Phase IB, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with NYHA II-III Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000931.
    >> Share

  9. GAO D, David C, Rosa MM, Costa J, et al
    The risk of mortality associated with opioid use in patients with acute heart failure: systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000954.
    >> Share

  10. GIUSEPPE DEL BUONO M, Crea F, Versaci F, Biondi-Zoccai G, et al
    NLRP3 inflammasome: a new promising therapeutic target to treat heart failure.
    J Cardiovasc Pharmacol. 2020 Nov 2. doi: 10.1097/FJC.0000000000000946.
    >> Share

    October 2020
  11. BERNIER TD, Buckley LF
    Cardiac Myosin Activation for the Treatment of Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000929.
    >> Share

  12. HU J, Wu Y, Zhou X, Wang X, et al
    Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    J Cardiovasc Pharmacol. 2020;76:445-451.
    >> Share

    August 2020
  13. LI C, Xia W, Wang L, Zhang J, et al
    Effect of renal denervation on cardiac function and inflammatory factors in heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Aug 24. doi: 10.1097/FJC.0000000000000899.
    >> Share

    July 2020
  14. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    >> Share

  15. PAPP Z, Agostoni P, Alvarez J, Bettex D, et al
    Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
    J Cardiovasc Pharmacol. 2020;76:4-22.
    >> Share

    June 2020
  16. SHEN JL, Xie XJ
    Insight into the Pro-inflammatory and Pro-Fibrotic Role of Macrophage in Heart Failure with Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2020 Jun 4. doi: 10.1097/FJC.0000000000000858.
    >> Share

  17. DENG T, Wei Z, Gael A, Deng X, et al
    Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
    J Cardiovasc Pharmacol. 2020;75:535-544.
    >> Share

    February 2020
  18. KELLY J, Cheng J, Malloy R, Lupi K, et al
    Comparison of positive inotropic agents in the management of acute decompensated heart failure.
    J Cardiovasc Pharmacol. 2020 Feb 20. doi: 10.1097/FJC.0000000000000811.
    >> Share

    January 2020
  19. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    >> Share

    December 2019
  20. LTEIF C, Arwood MJ, Kansal M, Cavallari LH, et al
    Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
    J Cardiovasc Pharmacol. 2019 Dec 31. doi: 10.1097/FJC.0000000000000779.
    >> Share

    November 2019
  21. DEL BUONO MG, Bonaventura A, Vecchie A, Wohlford GF, et al
    Sacubitril-Valsartan for the treatment of heart failure: Time for a paragon?
    J Cardiovasc Pharmacol. 2019 Nov 29. doi: 10.1097/FJC.0000000000000782.
    >> Share

    August 2019
  22. BLANTON RM
    cGMP Signaling and Modulation in Heart Failure.
    J Cardiovasc Pharmacol. 2019 Aug 27. doi: 10.1097/FJC.0000000000000749.
    >> Share

    July 2019
  23. PREEDY MEJ, Baliga RS, Hobbs AJ
    Multiplicity of Nitric Oxide and Natriuretic Peptide Signalling in Heart Failure.
    J Cardiovasc Pharmacol. 2019 Jul 24. doi: 10.1097/FJC.0000000000000724.
    >> Share

  24. ZENG H, Chen JX
    SIRTUIN 3, ENDOTHELIAL METABOLIC REPROGRAMMING AND HEART FAILURE WITH PRESERVED EJECTION FRACTION.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000719.
    >> Share

  25. BONAVENTURA A, Wohlford GF, Vecchie A, Van Tassel BW, et al
    In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
    J Cardiovasc Pharmacol. 2019;74:1-3.
    >> Share

    June 2019
  26. TOYODA S, Arikawa T, Inami S, Nishikawa R, et al
    Patients With CONgestive Heart Failure Benefit From Long-Term Treatment Effects With Novel Treatment Using Azosemide Compared With Furosemide Derived From Existing Retrospective Study Data: CONTENTED.
    J Cardiovasc Pharmacol. 2019;73:365-372.
    >> Share

    March 2019
  27. PINTO G, Tondi L, Gemma M, De Marco A, et al
    Real Life Indications to Sacubitril/Valsartan Treatment in Patients with Chronic Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2019 Mar 6. doi: 10.1097/FJC.0000000000000665.
    >> Share

    February 2019
  28. VICENT L, Esteban-Fernandez A, Gomez-Bueno M, De-Juan J, et al
    Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
    J Cardiovasc Pharmacol. 2019;73:118-124.
    >> Share

    January 2019
  29. HERPAIN A, Bouchez S, Girardis M, Guarracino F, et al
    Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.
    J Cardiovasc Pharmacol. 2019;73:3-14.
    >> Share

    December 2018
  30. DU AX, Westerhout CM, McAlister FA, Shanks M, et al
    The Titration and Tolerability of Sacubitril/Valsartan for Patients with Heart Failure in Clinical Practice.
    J Cardiovasc Pharmacol. 2018 Dec 10. doi: 10.1097/FJC.0000000000000643.
    >> Share

    November 2018
  31. LEENEN FH, Ahmad M, Marc Y, Llorens-Cortes C, et al
    Specific Inhibition of Brain Angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2018 Nov 30. doi: 10.1097/FJC.0000000000000638.
    >> Share

    May 2018
  32. VERRIER RL
    Ivabradine's Pleiotropic Profile: Can It Protect against Doxorubicin-Induced Heart Failure?
    J Cardiovasc Pharmacol. 2018 May 3. doi: 10.1097/FJC.0000000000000597.
    >> Share

  33. CHANG PC, Lu YY, Lee HL, Lin SF, et al
    Paradoxical Effects of Sodium-Calcium Exchanger Inhibition on Torsade de Pointes and Early Afterdepolarization in a Heart Failure Rabbit Model.
    J Cardiovasc Pharmacol. 2018 May 3. doi: 10.1097/FJC.0000000000000598.
    >> Share

    April 2018
  34. SALAH EM, Bastacky SI, Jackson EK, Tofovic SP, et al
    Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2018;71:205-214.
    >> Share

    November 2017
  35. COLE-JEFFREY CT, Pepine CJ, Katovich MJ, Grant MB, et al
    Beneficial Effects Of Angiotensin-(1-7) On Cd34 + Cells From Heart Failure Patients.
    J Cardiovasc Pharmacol. 2017 Nov 8. doi: 10.1097/FJC.0000000000000556.
    >> Share

    September 2017
  36. ABBATE A, Van Tassell BW
    Levosimendan in advanced heart failure: where do we stand?
    J Cardiovasc Pharmacol. 2017 Sep 25. doi: 10.1097/FJC.0000000000000539.
    >> Share

    August 2017
  37. ALTENBERGER J, Gustafsson F, Harjola VP, Karason K, et al
    Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications.
    J Cardiovasc Pharmacol. 2017 Aug 15. doi: 10.1097/FJC.0000000000000533.
    >> Share

    June 2017
  38. HANSEN MS, Andersen A, Holmboe S, Schultz JG, et al
    Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2017 Jun 19. doi: 10.1097/FJC.0000000000000508.
    >> Share

    April 2017
  39. BEI WJ, Wang K, Li HL, Lin KY, et al
    Safe Hydration Volume to Prevent Contrast-Induced Acute Kidney Injury and Worsening Heart Failure in Patients with Heart Failure and Preserved Ejection Fraction Following Cardiac Catheterization.
    J Cardiovasc Pharmacol. 2017 Apr 27. doi: 10.1097/FJC.0000000000000502.
    >> Share

    February 2017
  40. KOLPAKOV MA, Tilley DG, Sabri A
    Galphaq Signaling in the Regulation of Autophagy and Heart Failure.
    J Cardiovasc Pharmacol. 2017 Feb 3. doi: 10.1097/FJC.0000000000000471.
    >> Share

  41. HU J, Sharifi-Sanjani M, Tofovic SP
    Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding.
    J Cardiovasc Pharmacol. 2017;69:93-100.
    >> Share

    January 2017
  42. HOLMBOE S, Andersen A, Johnsen J, Nielsen JM, et al
    Inotropic Effects of Prostacyclins on the Right Ventricle Are Abolished in Isolated Rat Hearts With Right-Ventricular Hypertrophy and Failure.
    J Cardiovasc Pharmacol. 2017;69:1-12.
    >> Share

    April 2016
  43. HILLGAARD TK, Andersen A, Andersen S, Vildbrad MD, et al
    Levosimendan Prevents Pressure-Overload-induced Right Ventricular Failure.
    J Cardiovasc Pharmacol. 2016;67:275-82.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016